Luther King Capital Management (LKCM)’s Rani Therapeutics RANI Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.1K	Hold	58,000	–	–	﹤0.01%	613
2026 Q1	$42.6K	Hold	58,000	–	–	﹤0.01%	599
2025 Q4	$78.3K	Hold	58,000	–	–	﹤0.01%	603
2025 Q3	$29K	Hold	58,000	–	–	﹤0.01%	597
2025 Q2	$29.8K	Hold	58,000	–	–	﹤0.01%	584
2025 Q1	$73.1K	Buy	58,000 +25,000	+76%	+$37K	﹤0.01%	589
2024 Q4	$45.2K	Sell	33,000 -48,129	-59%	-$101K	﹤0.01%	586
2024 Q3	$175K	Buy	81,129 +25,000	+45%	+$71.6K	﹤0.01%	591
2024 Q2	$213K	Hold	56,129	–	–	﹤0.01%	578
2024 Q1	$175K	Hold	56,129	–	–	﹤0.01%	587
2023 Q4	$186K	Hold	56,129	–	–	﹤0.01%	567
2023 Q3	$122K	Hold	56,129	–	–	﹤0.01%	573
2023 Q2	$231K	Buy	+56,129	New	+$261K	﹤0.01%	558

Other funds holding RANI

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Luther King Capital Management (LKCM)'s RANI Position: Q2 2026 in Review

Luther King Capital Management (LKCM) held its Rani Therapeutics (RANI) position steady in Q2 2026 at 58,000 shares worth $44.1K. The position accounts for ﹤0.01% of the portfolio, ranked #613.

Luther King Capital Management (LKCM) first reported a position in RANI in Q2 2023 and has held it in 13 quarters since. The position peaked at $231K in Q2 2023. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

Luther King Capital Management (LKCM) held 58,000 shares of Rani Therapeutics worth $44.1K as of Q2 2026.
Luther King Capital Management (LKCM) left its Rani Therapeutics share count unchanged in Q2 2026.
Rani Therapeutics made up ﹤0.01% of Luther King Capital Management (LKCM)'s portfolio in Q2 2026, its #613 holding.
Luther King Capital Management (LKCM) first reported a position in Rani Therapeutics in Q2 2023 and has held it in 13 quarters since.
Luther King Capital Management (LKCM)'s Rani Therapeutics position peaked at $231K in Q2 2023.
68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q2 2026, filed 10 Aug 2026.